Sino Biopharmaceutical Limited: Business Overview, Financials & Competitive Analysis
Sino Biopharmaceutical Limited scores 7/10 on the AskCyborg Cyborg Score (Strong). Diversified oncology and therapeutic portfolio with strong recent earnings growth positions Sino Biopharmaceutical as a solid mid-cap pharmaceutical play in China's expanding healthcare market. Recent half-year earnings of 0.21 HKD per share exceeded estimates by 56.67%, demonstrating strong operational performance. The company maintains significant revenue generation and operates as.
What is Sino Biopharmaceutical Limited's industry? Sino Biopharmaceutical Limited (sinobiopharm.com) operates in Pharmaceuticals & Biotechnology. AskCyborg classifies Sino Biopharmaceutical Limited under Pharmaceuticals & Biotechnology in its company registry.
Sino Biopharmaceutical Limited is a research and development pharmaceutical conglomerate in China operating through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The comp...
Cyborg Score thesis
Diversified oncology and therapeutic portfolio with strong recent earnings growth positions Sino Biopharmaceutical as a solid...
Read the full analyst-debate transcript →Get the Latest Sino Biopharmaceutical Limited Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeSino Biopharmaceutical Limited Overview
Pro stress-test →Sino Biopharmaceutical Limited is a research and development pharmaceutical conglomerate in China operating through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company develops and manufactures a diverse portfolio of oncology, liver disease, and respiratory system medicines, positioning itself as an innovation-driven player in the Chinese pharmaceutical market.
Strategic Profile
Pro stress-test →The company offers a comprehensive oncology portfolio including anlotinib, penpulimab, and multiple targeted therapies with branded products like Focus V, Annike, and Yilishu. This diversified therapeutic approach combined with both Western and modernized Chinese medicine capabilities provides competitive differentiation in a large and growing market.
Competitive Landscape
Pro stress-test →Sino Biopharmaceutical competes in China's dynamic pharmaceutical market against both domestic players and multinational pharma companies. The company differentiates through its focus on oncology innovation, modernized Chinese medicines, and a diversified therapeutic portfolio. Key competitive advantages include manufacturing scale, distribution networks, and R&D capabilities in high-growth therapeutic areas.
Industry Context
Sino Biopharmaceutical Limited operates in Pharmaceuticals & Biotechnology.
Key facts
Headquarters: Hong Kong, China · Revenue: 19.26B HKD (half-year 2025)